Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform Details at ESCMID London Meeting

Published: Apr 02, 2012

EW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) announced that the Company yesterday made its first peer-reviewed presentation of its novel AmpiProbe™ platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

Back to news